Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > duration

: 4 hours (IR); 12 hours (ER)

or Hours

or Hours per application

Use the filters below to narrow your results.

Ascorbic acid (vitamin C) (1) · Bisacodyl (1) · Ciclopirox (1) · Clotrimazole (1) · Docusate (sodium or calcium) (1) · Guaifenesin (1) · Hydroquinone (1) · Lactulose (1) · Mupirocin (1) · Nystatin (1) · Polyethylene glycol 3350 (PEG 3350) (1)

Bactroban, Centany (1) · Colace (sodium), Surfak (calcium); many generics OTC (1) · Dulcolax, Correctol, Bisac-Evac (1) · Generic; huge OTC presence (1) · Kristalose, Constulose, Generlac, Enulose (1) · Lotrimin, Mycelex, Gyne-Lotrimin; OTC widely (1) · Lustra, EpiQuin Micro, Melquin, Tri-Luma (with tretinoin and fluocinolone) (1) · MiraLAX (OTC), GlycoLax, GoLYTELY (with electrolytes for bowel prep), CoLyte, MoviPrep, NuLYTELY (1) · Mucinex, Robitussin, Tussin (1) · Mycostatin, Nystop, Nyamyc, Bio-Statin (1) · Penlac (nail lacquer), Loprox (cream/lotion/shampoo) (1)

None (5) · '"`UNIQ--vote-000009FD-QINU`"' Active against gram-positive cocci including MRSA; the unique target underlies the absence of cross-resistance with other antibiotic classes. High-level resistance (plasmid-mediated mupA) is rising and limits prolonged or repeated use'"`UNIQ--ref-000009FE-QINU`"'. (1) · '"`UNIQ--vote-00000D11-QINU`"' Same mechanistic family as amphotericin B but with prohibitive systemic toxicity at therapeutic doses, hence restriction to topical and luminal-gut indications. No clinically meaningful resistance after decades of use'"`UNIQ--ref-00000D12-QINU`"'. (1) · '"`UNIQ--vote-0000104D-QINU`"' Adequate hydration is at least as important as the drug in producing the expectorant effect clinically. Used in combination with dextromethorphan, decongestants, or antihistamines in many proprietary OTC cold preparations. (1) · '"`UNIQ--vote-00001067-QINU`"' Chronic use is associated with cathartic colon (colonic dilation, loss of haustration), hypokalemia, and laxative dependence; reserved for short-term use or bowel prep with breaks between courses'"`UNIQ--ref-00001068-QINU`"'. (1) · '"`UNIQ--vote-00001233-QINU`"' Onychomycosis cure rates with nail lacquer are modest (mycologic cure ~30-50%, complete cure ~5-12% at 48 weeks); oral terbinafine remains substantially more effective when systemic therapy is acceptable'"`UNIQ--ref-00001234-QINU`"'. (1) · '"`UNIQ--vote-0000132D-QINU`"' Electrolyte-balanced bowel-prep formulations are designed to be iso-osmotic with plasma so the volume passes through without net fluid or electrolyte shifts, the basis of their safety for whole-bowel evacuation. (1)

100-200 mg PO once or twice daily; pediatric weight-based (1) · 200-400 mg PO q4h (IR); 600-1200 mg PO q12h (Mucinex 12-Hour ER) (1) · 5-15 mg PO once at bedtime; 10 mg PR for faster effect; bowel prep regimens use higher single doses (1) · Apply thin layer to hyperpigmented areas BID; limit to 4-6 month courses to avoid ochronosis (1) · Constipation: 15-30 mL PO daily (titrate to 1-2 soft stools/day); hepatic encephalopathy: 20-30 g (30-45 mL) PO/PR every 1-2 hours acutely until soft stools, then BID-QID to target 2-3 soft stools/day (1) · Constipation: 17 g (one capful) PO daily dissolved in 4-8 oz fluid; bowel prep: 4 L of PEG-electrolyte solution split-dose evening before and morning of procedure (1) · General supplementation 75-90 mg/d (RDA); scurvy treatment 100-1000 mg/d for several weeks; megadose claims unsupported (1) · Oral: 4-6 mL (400,000-600,000 units) suspension QID swish-and-swallow; topical: BID-QID; vaginal tablet 1 daily for 2 weeks (1) · Topical cream/lotion BID; shampoo twice weekly; nail lacquer (Penlac) once daily for up to 48 weeks (1) · Topical: 1% cream BID × 2-4 weeks; vaginal: 1% or 2% cream nightly × 7 days, or 100/200/500 mg vaginal tablet single or 3-day regimens; troche: 10 mg PO five times daily × 2 weeks for thrush (1) · Topical: apply small amount to affected area TID × 5-10 days; nasal: apply half the contents of a single-use tube into each nostril BID × 5 days (1)

0.77% topical cream, lotion, suspension; 1% shampoo; 8% nail lacquer (Penlac) (1) · 1% topical cream, lotion, solution; 1%, 2% vaginal cream; 100, 200, 500 mg vaginal tablets; 10 mg oral troches; combination with betamethasone (Lotrisone, Rx) (1) · 10 g/15 mL solution (Constulose); 10 g, 20 g powder packets (Kristalose) (1) · 100, 200, 400 mg IR tablets; 600 mg, 1200 mg Mucinex ER tablets; many liquid formulations and combination products with dextromethorphan, pseudoephedrine, antihistamines (1) · 100, 250, 500, 1000 mg tablets, chewables, gummies, effervescent; IV (specialty) (1) · 100,000 units/mL oral suspension; 500,000 unit tablets; 100,000 units/g cream, ointment, powder; vaginal tablets (1) · 17 g (OTC) and 14 g (Rx) powder packets; 238, 510, 527 g bottles; PEG-electrolyte preparations 4 L (GoLYTELY, NuLYTELY) (1) · 2% ointment; 2% cream; 2% nasal ointment (Bactroban Nasal) (1) · 4% prescription cream/lotion; OTC 2% withdrawn in US (2020 CARES Act); compounded higher strengths available (1) · 5 mg enteric-coated tablets; 10 mg rectal suppositories; OTC and Rx (1) · 50, 100, 250 mg capsules; 50 mg/5 mL syrup; OTC (1)

2.4 g/d (1) · 30 mg/d for short-term use (1) · 4% topical; limit duration of use (1) · BID topical; once daily nail lacquer (1) · Indication-specific (1) · Indication-specific; bowel prep regimens reach 4 L cumulative (1) · Indication-specific; HE may require high-volume dosing (1) · Limit topical to 10-day courses to reduce resistance pressure (1) · Topical: BID; troche: 5×/day (1) · UL 2000 mg/d in adults (1) · ~500 mg/d typical (1)

especially in acute HE) (1) · intranasal (1) · IV (1) · Oral (6) · Oral (topical action; minimal systemic absorption) (1) · oral troche (1) · rectal (2) · rectal (enema (1) · Topical (5) · vaginal (2)

1-3 days (1) · 30 minutes (1) · Constipation: 1-3 days; bowel prep: 1-3 hours after starting (1) · Constipation: 24-48 hours; HE: ammonia reduction within hours of stool production (1) · Days (2) · Days for dermatophyte clearance; nail clearance over months (1) · Days for symptom improvement in scurvy (1) · PO 6-12 hours; PR 15-60 minutes (1) · Symptom relief within days (1) · Visible lightening at 4-12 weeks (1)

<0.1% systemic absorption (PEG 3350 is too large to absorb intact) (1) · <3% systemic absorption (the basis of the safety and mechanism)'"`UNIQ--ref-00000F5E-QINU`"' (1) · Essentially zero systemic absorption from oral or topical routes — the topical-action-only profile is the basis of its safety'"`UNIQ--ref-00000D18-QINU`"' (1) · High (oral)'"`UNIQ--ref-00001051-QINU`"' (1) · Local action; minimal systemic effect (1) · Low systemic absorption (enteric coating delivers drug to colon)'"`UNIQ--ref-0000106C-QINU`"' (1) · Topical with limited but measurable systemic absorption'"`UNIQ--ref-00001219-QINU`"' (1) · Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"' (1) · Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"' (1) · Topical; minimal systemic absorption'"`UNIQ--ref-00000A03-QINU`"' (1) · ~70-90% at typical doses; saturable at high doses (>500 mg) (1)

Generally avoided in pregnancy.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered acceptable for short-term use.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered acceptable.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe (minimal systemic absorption).[[[Pharmacopedia:Citation needed|citation needed]]] (2) · Generally considered safe due to minimal systemic absorption.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe in pregnancy (no systemic absorption).[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe; minimal systemic exposure.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Safe at routine doses; routinely supplemented in pregnancy.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Topical and vaginal generally considered safe; widely used.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

OTC (lower strengths) and [[USLegal:Prescription only|Rx-only]] (combination with betamethasone) in US (1) · OTC (MiraLAX) and [[USLegal:Prescription only|Rx-only]] (electrolyte solutions for bowel prep) in US (1) · OTC in US (4) · [[USLegal:Prescription only|Rx-only]] in US (4) · [[USLegal:Prescription only|Rx-only]] in US since 2020 (OTC 2% formulations withdrawn under CARES Act due to safety concerns) (1)

Showing below up to 11 results in range #1 to #11.

A

Ascorbic Acid

B

Bisacodyl

C